Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management
- PMID: 32271125
- PMCID: PMC7196360
- DOI: 10.1089/met.2020.0037
Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management
Keywords: COVID-19; cardiovascular disease; endothelial dysfunction; insulin resistance; obesity; type 2 diabetes.
Conflict of interest statement
M.R. is currently Director, Clinical Medical and Regulatory Department, Novo Nordisk Europe East and South. A.P.S. is currently Vice-President, National Diabetes Commission, Ministry of Health, Romania. No competing financial interests exist for the remaining authors.
References
-
- World Health Organization. Coronavirus disease (COVID-19) pandemic. Accessed at https://www.who.int/emergencies/diseases/novel-coronavirus-2019 accessed on March28, 2020
-
- Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020. March 12 [Epub ahead of print]; DOI: 10.1016/j.ijid.2020.03.017 - DOI
-
- Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23:623. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical